Metformin is widely considered the safest drug for type 2 diabetes. It has been used for over 60 years, carries a very low risk of dangerously low blood sugar when used alone, and is the recommended first-line treatment by every major diabetes organization in the world. But “safest” depends on your individual health profile, so understanding how the major drug classes compare on key safety measures can help you have a more informed conversation with your doctor.
Why Metformin Is the Standard Starting Point
Metformin works by reducing the amount of sugar your liver releases into the bloodstream and by helping your cells respond better to insulin. Unlike some older diabetes drugs, it does not force your pancreas to produce more insulin, which is why it rarely causes hypoglycemia (blood sugar dropping dangerously low) when taken on its own.
The most common side effects are gastrointestinal: diarrhea, nausea, gas, stomach discomfort, and indigestion. About 20% of people taking metformin experience some degree of GI trouble, and roughly 5% find it bothersome enough to stop taking the medication. Starting at a low dose and increasing gradually, or switching to an extended-release form, helps most people tolerate it. Metformin is also weight-neutral or slightly weight-negative, meaning it won’t cause the kind of weight gain that some other diabetes drugs do.
The one serious risk associated with metformin is lactic acidosis, a dangerous buildup of acid in the blood. This is extremely rare and occurs almost exclusively in people with significant kidney disease. If your kidneys are functioning normally, the risk is negligible. Your doctor will check your kidney function before prescribing metformin and periodically afterward.
How Other Drug Classes Compare on Safety
SGLT2 Inhibitors
SGLT2 inhibitors work by causing your kidneys to excrete excess sugar through urine. They have strong evidence for protecting the heart and kidneys. In clinical trials, these drugs slow the long-term decline in kidney function and reduce the risk of heart failure hospitalization. They also do not typically cause hypoglycemia when used alone.
The trade-off is a small set of distinct risks. Because they increase sugar in the urinary tract, genital yeast infections and urinary tract infections are more common. A rare but serious concern is euglycemic ketoacidosis, a form of diabetic ketoacidosis that occurs even when blood sugar levels appear normal. This happens at a rate of about 0.5 per 1,000 patient-years. It’s uncommon but can be dangerous if not recognized. Symptoms include nausea, vomiting, abdominal pain, and unusual fatigue, particularly during illness, surgery, or dehydration. There is also a very small risk of a rare genital infection called Fournier’s gangrene, though reported cases remain extremely uncommon.
When you first start an SGLT2 inhibitor, your kidney filtration rate often dips in the first two weeks. This can look alarming on lab work, but research from the American Heart Association shows that patients who experience this early dip actually have better long-term kidney and cardiovascular outcomes. A decline greater than 30% is uncommon (only 3-4% of patients in major trials) and should prompt investigation for other causes like dehydration.
GLP-1 Receptor Agonists
GLP-1 receptor agonists (the drug class that includes semaglutide and liraglutide) mimic a hormone that stimulates insulin release only when blood sugar is elevated, which makes hypoglycemia uncommon when they’re used without insulin or sulfonylureas. They also promote significant weight loss, which is a meaningful benefit for many people with type 2 diabetes.
The main safety issue is gastrointestinal. Nausea, vomiting, and diarrhea are common, especially during dose escalation, and can be severe enough to require stopping treatment in some patients. These side effects tend to improve over weeks as the body adjusts.
An FDA warning exists regarding a potential link to medullary thyroid cancer, based on rodent studies. However, a 2025 study found no statistically significant increase in overall thyroid cancer risk in humans taking these medications. Thyroid cancer diagnoses were elevated during the first 12 months of use, but this appeared to be a detection bias: patients starting GLP-1 drugs were significantly more likely to receive thyroid ultrasounds (2.1% versus 1.5% of patients on other diabetes medications at 12 months), which naturally catches more existing cancers. After the first year, no elevated risk was found. The FDA still advises against using these drugs if you have a personal or family history of medullary thyroid cancer or a condition called MEN2.
DPP-4 Inhibitors
DPP-4 inhibitors work through a similar pathway as GLP-1 drugs but are less potent. They are very well tolerated, with a low risk of hypoglycemia and minimal GI side effects. They don’t cause weight loss, but they don’t cause weight gain either. They are often considered when someone can’t tolerate metformin and doesn’t need the stronger blood sugar lowering or weight loss effects of other options. Their cardiovascular profile is neutral: they neither increase nor decrease heart risk in major trials.
Sulfonylureas
Sulfonylureas are among the oldest diabetes drugs and remain widely prescribed because they are inexpensive and effective at lowering blood sugar. However, they carry the highest hypoglycemia risk of any oral diabetes medication. They work by forcing the pancreas to release more insulin regardless of your current blood sugar level, which means blood sugar can drop too low, especially if you skip a meal or exercise more than usual. They also tend to cause weight gain. For these reasons, they are generally considered less safe than the drug classes above, particularly for older adults who are more vulnerable to falls and other consequences of low blood sugar.
Thiazolidinediones (TZDs)
Pioglitazone, the main drug in this class still in use, improves insulin sensitivity but comes with notable safety concerns. It can cause fluid retention, which worsens heart failure, and is contraindicated in people with moderate to severe heart failure. Liver function needs to be monitored during treatment. It also causes weight gain and has been associated with an increased risk of bone fractures, particularly in women. These concerns have pushed TZDs lower on the prescribing priority list compared to newer options.
Hypoglycemia Risk: The Most Practical Safety Measure
For many people, the most relevant daily safety concern is hypoglycemia. Low blood sugar can cause confusion, dizziness, falls, loss of consciousness, and in severe cases, seizures. Metformin, SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors are all not typically associated with hypoglycemia when used as standalone treatments. The risk increases substantially when any of these are combined with insulin or a sulfonylurea. Sulfonylureas and insulin are the primary drivers of hypoglycemia in type 2 diabetes treatment.
What “Safest” Really Depends On
No single drug is universally safest for every person with type 2 diabetes. Metformin holds its first-line position because it has the longest safety track record, the lowest hypoglycemia risk, no weight gain, and is effective and inexpensive. But individual health factors shift the equation. Someone with heart failure or chronic kidney disease may benefit more from an SGLT2 inhibitor’s protective effects, even though it introduces a small ketoacidosis risk. Someone who needs significant weight loss may find the benefits of a GLP-1 receptor agonist outweigh its GI side effects.
The practical answer for most people newly diagnosed with type 2 diabetes: metformin is the safest starting point. If you need additional medication, the newer classes (SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors) all have favorable safety profiles compared to the older sulfonylureas and TZDs, with the added advantage of protecting the heart and kidneys rather than simply lowering blood sugar numbers.